Hematopoietic stem cell transplantation in its 60s: A platform for cellular therapies

Christian Chabannon; Jurgen Kuball; Attilio Bondanza; Francesco Dazzi; Paolo Pedrazzoli; Antoine Toubert; Annalisa Ruggeri; Katharina Fleischhauer; Chiara Bonini

doi:10.1126/scitranslmed.aap9630

Hematopoietic stem cell transplantation in its 60s: A platform for cellular therapies

Christian Chabannon, Jurgen Kuball, Attilio Bondanza, Francesco Dazzi, Paolo Pedrazzoli, Antoine Toubert, Annalisa Ruggeri, Katharina Fleischhauer, Chiara Bonini

Research output: Contribution to journal › Review article › peer-review

Abstract

Over the last 60 years, more than a million patients received hematopoietic cell transplantation. Having incorporated multiple changes in clinical practices, it remains a complex procedure facing a dual challenge: cure of the underlying disease and prevention of relapse while controlling potentially severe complications. Improved understanding of underlying biological processes resulted in the design of innovative therapies engineered from defined cell populations and testing of these therapies as addition or substitution at virtually every step of the procedure. This review provides an overview of these developments, many of them now applied outside the historical field of hematopoietic cell transplantation.

Original language	English
Journal	Science Translational Medicine
Volume	10
Issue number	436
DOIs	https://doi.org/10.1126/scitranslmed.aap9630
Publication status	Published - Apr 11 2018

Access to Document

10.1126/scitranslmed.aap9630

Cite this

@article{ca6f165df5bc4c9bae4678529df9471e,

title = "Hematopoietic stem cell transplantation in its 60s: A platform for cellular therapies",

abstract = "Over the last 60 years, more than a million patients received hematopoietic cell transplantation. Having incorporated multiple changes in clinical practices, it remains a complex procedure facing a dual challenge: cure of the underlying disease and prevention of relapse while controlling potentially severe complications. Improved understanding of underlying biological processes resulted in the design of innovative therapies engineered from defined cell populations and testing of these therapies as addition or substitution at virtually every step of the procedure. This review provides an overview of these developments, many of them now applied outside the historical field of hematopoietic cell transplantation.",

author = "Christian Chabannon and Jurgen Kuball and Attilio Bondanza and Francesco Dazzi and Paolo Pedrazzoli and Antoine Toubert and Annalisa Ruggeri and Katharina Fleischhauer and Chiara Bonini",

note = "Copyright {\textcopyright} 2018 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.",

year = "2018",

month = apr,

day = "11",

doi = "10.1126/scitranslmed.aap9630",

language = "English",

volume = "10",

journal = "Science Translational Medicine",

issn = "1946-6234",

publisher = "American Association for the Advancement of Science",

number = "436",

}

TY - JOUR

T1 - Hematopoietic stem cell transplantation in its 60s

T2 - A platform for cellular therapies

AU - Chabannon, Christian

AU - Kuball, Jurgen

AU - Bondanza, Attilio

AU - Dazzi, Francesco

AU - Pedrazzoli, Paolo

AU - Toubert, Antoine

AU - Ruggeri, Annalisa

AU - Fleischhauer, Katharina

AU - Bonini, Chiara

PY - 2018/4/11

Y1 - 2018/4/11

N2 - Over the last 60 years, more than a million patients received hematopoietic cell transplantation. Having incorporated multiple changes in clinical practices, it remains a complex procedure facing a dual challenge: cure of the underlying disease and prevention of relapse while controlling potentially severe complications. Improved understanding of underlying biological processes resulted in the design of innovative therapies engineered from defined cell populations and testing of these therapies as addition or substitution at virtually every step of the procedure. This review provides an overview of these developments, many of them now applied outside the historical field of hematopoietic cell transplantation.

AB - Over the last 60 years, more than a million patients received hematopoietic cell transplantation. Having incorporated multiple changes in clinical practices, it remains a complex procedure facing a dual challenge: cure of the underlying disease and prevention of relapse while controlling potentially severe complications. Improved understanding of underlying biological processes resulted in the design of innovative therapies engineered from defined cell populations and testing of these therapies as addition or substitution at virtually every step of the procedure. This review provides an overview of these developments, many of them now applied outside the historical field of hematopoietic cell transplantation.

U2 - 10.1126/scitranslmed.aap9630

DO - 10.1126/scitranslmed.aap9630

M3 - Review article

C2 - 29643233

VL - 10

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 436

ER -

Hematopoietic stem cell transplantation in its 60s: A platform for cellular therapies

Abstract

Access to Document

Fingerprint

Cite this